Table 4. Assessment for early response to 0.5 vs 2.0 mg dose of ranibizumab (week 4 and week 8).

	P-value (week 4)	P-value (week 8)	P-value (month 12)
a. Assessment of early course of vision outcome
0.5 mg	0.414	0.202	0.421
2.0 mg	0.019	0.021	0.038
b. Assessment of early course of subretinal fluid reduction
0.5 mg	0.058	0.020	0.034
2.0 mg	<0.001	<0.001	0.414

	P-value Pre-treatment to week 4	P-value Pre-treatment to week 8	P-value (week 8)	P-value (last visit)
c. Assessment of early course of % reduction in PED reduction
	0.32	0.08	0.004	0.71